Table 1 Comparison of clinical characteristics between MRD + and MRD- patients according to DTA genes and non-DTA genes
Characteristic | All patients (N = 152) | DTA genes | Non-DTA genes | ||||
|---|---|---|---|---|---|---|---|
MRD positive (n = 13) | MRD negative (n = 27) | P Value | MRD positive (n = 52) | MRD negative (n = 98) | P Value | ||
Median age (range) | 44(12–67) | 50(21–64) | 48(23–61) | 0.194 | 43(13–64) | 43(12–67) | 0.442 |
Sex, n (%) | Â | Â | Â | 0.577 | Â | Â | 0.742 |
Male | 78(51.3) | 7(53.8) | 12(44.4) | Â | 28(53.8) | 50(51.0) | Â |
Female | 74(48.7) | 6(46.2) | 15(55.6) | Â | 24(46.2) | 48(49.0) | Â |
Disease, n (%) | Â | Â | Â | 0.736 | Â | Â | 0.881 |
AML | 127(83.6) | 10(76.9) | 22(81.5) | Â | 44(84.6) | 82(83.7) | Â |
MDS | 25(16.4) | 3(23.1) | 5(18.5) | Â | 8(15.4) | 16(16.3) | Â |
Remission status at time of HCT n (%) | Â | Â | Â | 0.201 | Â | Â | 0.269 |
CR1 | 103(67.8) | 6(46.1) | 18(66.7) | Â | 31(59.6) | 71(72.5) | Â |
≥CR2 | 27(17.8) | 4(30.8) | 2(7.4) |  | 11(21.2) | 15(15.3) |  |
No CR | 22(14.4) | 3(23.1) | 7(25.9) | Â | 10(19.2) | 12(12.2) | Â |
DRI-R, n (%) | Â | Â | Â | 0.564 | Â | Â | 0.038 |
Low/Intermediate | 94(61.8) | 8(61.5) | 14(51.9) | Â | 26(50.0) | 66(67.3) | Â |
High/Very high | 58(38.2) | 5(38.5) | 13(48.1) | Â | 26(50.0) | 32(32.7) | Â |
HLA match, n (%) | Â | Â | Â | 0.807 | Â | Â | 0.210 |
MMRD/MMUD | 127(83.6) | 11(84.6) | 22(81.5) | Â | 41(78.8) | 85(86.7) | Â |
MRD/MUD | 25(16.4) | 2(15.4) | 5(18.5) | Â | 11(21.2) | 13(13.3) | Â |
Donor sex, n (%) | Â | Â | Â | 0.090 | Â | Â | 0.145 |
Male | 103(67.8) | 11(84.6) | 15(55.6) | Â | 39(75.0) | 62(63.3) | Â |
Female | 49(32.2) | 2(15.4) | 12(44.4) | Â | 13(25.0) | 36(36.7) | Â |